Valneva’s Perfect Storm: Legal Headwinds, Clinical Controversy, and a Stock at Rock Bottom

Valneva shares hit 52-week low after Phase 3 Lyme vaccine data fails statistical threshold, sparking legal probe and deep analyst divide.

The French vaccine developer Valneva finds itself navigating treacherous waters as a cascade of setbacks—clinical, legal, and financial—converge to push its shares to fresh lows. Trading at €2.34, the stock has slumped to a new 52-week trough, erasing roughly 55% from its August 2025 peak and shedding nearly 39% of its value since the start of the year.

A Clinical Disappointment Sparks Legal Scrutiny

The turmoil traces back to March 23, when Valneva and its partner Pfizer unveiled Phase 3 data from the VALOR trial for their Lyme disease vaccine candidate, LB6V. While the companies highlighted a clinical efficacy rate above 70%, the study failed to meet its primary statistical endpoint—the 95% confidence interval threshold—during the first predefined analysis. The culprit: fewer Lyme disease cases than anticipated occurred during the trial period, muddying the statistical picture. A second predefined analysis did satisfy the statistical requirements, but the damage to investor confidence was already done.

The market reaction was brutal. Valneva’s American depositary receipts cratered by more than a third on the day of the announcement. That sell-off has now drawn the attention of the US law firm Pomerantz, which launched an investigation on April 28 into whether the company’s management made misleading statements about the trial’s progress prior to the data release.

Analyst Divergence Reaches Extreme Levels

The clinical uncertainty has split the analyst community like few other stocks. Jefferies maintains a bullish stance with a price target of $15, while Goldman Sachs has slapped a “Sell” rating on the shares and set a target of just €2.15—a chasm that underscores the deep disagreement over Valneva’s prospects.

Guggenheim, which has kept a Buy recommendation, recently trimmed its price target from $13 to $11 but remains above the consensus. The firm expects first-quarter revenues of €49.1 million when Valneva reports on May 7, well ahead of the market consensus of €45.1 million. The critical question for Guggenheim is whether Valneva’s established travel vaccines—IXIARO for Japanese encephalitis and DUKORAL for cholera—can generate sufficient cash flow to fund the regulatory processes ahead.

Pfizer’s Commitment Offers a Glimmer of Hope

Despite the statistical stumble, Pfizer has not walked away from the Lyme program. CEO Thomas Lingelbach confirmed that the partnership intends to file a Biologics License Application with the FDA and a marketing authorization application with the EMA in the second half of 2026. Optimists interpret this as a strong strategic vote of confidence; skeptics counter that the regulatory pathway remains unclear and that the cash burn shows no signs of easing.

Pipeline Catalysts and Commercial Realities

Beyond Lyme, Valneva has several other shots on goal. Phase 2 data for its Shigella vaccine candidate are expected later this year, offering a potential sentiment shift if the results are compelling. In Brazil, a pilot campaign for the Chikungunya vaccine IXCHIQ has already inoculated more than 12,000 people, and Valneva plans to present real-world data from that effort. However, the US regulatory picture for IXCHIQ remains clouded: the FDA suspended its approval in August 2025, and Valneva voluntarily withdrew its application in January 2026.

Financial Strain Beneath the Surface

Valneva entered 2026 with what appeared to be a stable balance sheet. Full-year 2025 revenues came in at €174.7 million, with product sales contributing €157.9 million. The company ended the year with €109.7 million in cash, aided by a sharp reduction in cash burn and a successful refinancing. But the net loss ballooned to €115.2 million, raising questions about sustainability.

For 2026, management has guided for revenues between €155 million and €170 million, leaning heavily on the commercial performance of IXCHIQ and the travel vaccine portfolio. The first-quarter report on May 7 will provide an early test of whether those targets remain achievable.

With the legal probe underway, a pivotal data readout for Shigella on the horizon, and the Lyme regulatory clock ticking toward a mid-2026 filing window, Valneva faces a defining stretch. The next few months will determine whether the company can emerge from this storm with its pipeline intact—or whether the headwinds prove too strong.